March 2007 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

March 2007

Pharmaceutical Technology


Bigger cuts

Despite its growth, the FDA budget is barely a blip in the administration's $2.9-trillion federal spending plan, or in the $700-billion budget for the US Department of Health and Human Services (most of which is mandated spending for Medicare and Medicaid). Thus, to curb the "unsustainable growth of federal entitlement programs," the Bush administration seeks more than $100 billion in Medicare savings over five years, largely by freezing payments to hospitals, nursing homes, and physicians.

Healthcare providers immediately set in motion plans to kill the fee cuts, while Congressional Democrats fumed that the budget was dead on arrival. Administration supporters described the administration's proposal as the "opening bid" in the battle to reduce the budget deficit, a task made more difficult by huge increases in spending for the war in Iraq.

A controversial proposal is to have wealthier seniors pay higher premiums for Medicare benefits, including premiums for Medicare prescription drug plans. Additional cuts would hit Medicaid and the Children's Health Insurance Program (CHIP), which has to be reauthorized by Congress this year. With pressure high on the legislators to find more money for Medicare, CHIP, and other health programs, added funding for FDA is far from a done deal.

-Jill Wechsler

VACCINES

HHS Offers Liability Protections for Flu Vaccine Manufacturers



Washington, DC (Jan. 26)—The US Department of Health and Human Services (HHS, http://www.hhs.gov/) has granted targeted liability protections for manufacturers of a vaccine to prevent a pandemic of influenza A (H5N1).

The new declaration states that manufacturers of vaccines used to prevent potential avian pandemics will receive immunity from product liability claims. According to the Federal Register notice, it is "intended to alleviate certain liability concerns associated with pandemic countermeasures, and, therefore, ensure that the countermeasures are available and can be administered in the event an avian influenza virus spreads and evolves into a strain capable of causing a pandemic."

With this measure, HHS hopes to encourage the development, clinical testing, manufacture, and distribution of an influenza A vaccine. The declaration went into effect Dec. 1, 2006 and continues through Feb. 28, 2010.

–Brianne Harrison

PROCESSING INGREDIENTS

FDA Proposes Ban on Cattle Tissue in Drugs



Rockville, MD (Jan. 12)—To prevent the spread of bovine spongiform encephalopathy (BSE) and related diseases, the US Food and Drug Administration ( http://www.fda.gov/) has proposed banning certain cattle tissues and tissue products from the manufacture of drugs for human and ruminant use.

The proposal, "Use of Materials Derived from Cattle in Medical Products Intended for Use in Humans and Drugs Intended for Use in Ruminants; Proposed Rule" (published in the Jan.12 Federal Register, pp. 1581–1619), estimates that cattle products of some kind are used in 75% of pharmaceutical manufacturing—and 90% of biotechnology processes. The proposal notes, however, that the agency has reviewed 10 years of data on cattle products used in drug-manufacturing and "we are aware of no approved drugs and no investigational drugs that are manufactured with cattle material that would be prohibited under this proposed rule ...."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here